Objectif
This project aims to develop a protocol for effective immunotherapy of breast and ovarian cancer based on a prime boost strategy and the MUC1 antigen which is over-expressed and aberrantly glycosylated in 90% of these malignancies. The strategy will combine cDNA priming with a glycoprotein boost. Different cancer-associated glycoforms of MUC1 will be produced in CHO cells, wild type, and modified by transfection of specific glycosyl transferases. The glycoproteins will be purified, characterised and comparatively evaluated with MUC1 cDNA for efficacy in tumour rejection in mouse models. Chemo-enzymically synthesised MUC1 glycopeptides will be used to evaluate immune responses. Conditions for production to GMP standard of MUC1 cDNA and the selected glycoprotein will be established to prepare for a clinical study. The pattern of glycosylation in cancer cells will be defined with microarray technology and MUC1 cDNA modified.
Champ scientifique
Appel à propositions
Data not availableRégime de financement
CSC - Cost-sharing contractsCoordinateur
WC2A 3PX LONDON
Royaume-Uni